Citations

Clear

4564 citation(s) found for "Yu, Virginia".

All‐Suture Knotless Suture Anchor Repair of Scapholunate Ligament: The Double‐Pulley Repair
Hassebrock, Jeffrey D. , Hinckley, Nathaniel B. , Kozusko, Steven D. , Freilich, Aaron M. , Dacus, A. Rashard , DeGeorge, Brent R. , Hassebrock, Jeffrey D , Chhabra, Anikar

Mayo Clinic

Arthroscopy Techniques | November 26, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1016/j.eats.2024.103333 | PMID 40453007 Get It

Abstract Symptomatic scapholunate tears are a common traumatic problem in the wrist. This article demonstrates a technique for reducing and stabilizing complete scapholunate tears. The purpose is to provide a detailed description of the technique, highlight potential advantages, and discuss preliminary clinical results. Technique Video video See video under supplementary data.
LTBK-07. PROGRESSION-FREE AND OVERALL SURVIVAL RESULTS OF ECOG-ACRIN E3F05: A PHASE 3 INTERGROUP TRIAL OF RADIATION ± TEMOZOLOMIDE FOR GRADE II GLIOMAS
Schiff, David , O’Neill, Anne, Brown, Paul D. , Jenkins, Robert B. , Youssef, Emad, Uhm, Joon H. , Giglio, Pierre , Cavaliere, Robert , Ashby, Lynn S., Kleinberg, Lawrence , Schiff, David, Mehta, Minesh P. , Giannini, Caterina , Suh, John H. , Moots, Paul L

Mayo Clinic

Neuro-Oncology | November 23, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii2

10.1093/neuonc/noae165.1303 Get It

Abstract BACKGROUND Both radiation and temozolomide (TMZ) have meaningful single-modality anti-tumor activity against low-grade gliomas. ECOG-ACRIN E3F05 tested whether combined therapy with radiation and temozolomide is more effective than radiation alone in patients with grade II gliomas. METHODS Patients with grade II gliomas (central pathology review performed post hoc), no prior radiation/chemotherapy, and either age > 40, uncontrolled symptoms/seizures, or progression after initial observation were randomized 1:1 to radiation 50.4 Gy alone in 28 fractions (Arm A) versus radiation 50.4 Gy with concomitant and 12 four-week cycles of post-radiation TMZ (Arm B). Randomization was stratified by 1p/19q codeletion status, age, KPS, pre-operative tumor diameter, and contrast enhancement. The primary endpoint was progression-free survival (PFS); overall survival (OS), quality of life, cognition, severe toxicities, and impact of codeletion status were secondary objectives. RESULTS The trial opened 1/09. Accrual was stopped in 1/14 after RTOG 9802 reported benefit from the addition of PCV chemotherapy to radiation in grade II gliomas. A total of 172 subjects were enrolled. Median age was 44 (range 19-78) and 54% male. 1p/19q codeletion was present in 44%. NCI CTCAE (version 4) grade 3+ toxicity was more common in participants treated with TMZ: thrombocytopenia (11%) and neutropenia (5%) versus none in the radiation alone arm. With a median follow-up of 117 months, OS was superior in Arm B (HR 0.54, 95% CI 0.31-0.95, stratified log-rank p value 0.03). OS HRs were 0.56 and 0.53 for subjects with and without 1p/19q codeleted tumors, respectively. PFS did not differ between Arms A and B (HR 0.76, 95% CI 0.44-1.28, p = 0.30). Five and ten-year OS were 78% and 70% in Arm B versus 70% and 47% in Arm A. CONCLUSION The addition of temozolomide to radiation improves overall survival in both co-deleted and non-co-deleted grade II gliomas.
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Mellinghoff, Ingo K. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Gordon, Gary, Lassman, Andrew B. , Lim, Michael , Perry, James , Wen, Patrick Y. , Yung, W.K. Alfred , Berry, Nicholas , Graves, Todd, Detry, Michelle A. , Hyddmark, Emma Maria Viktoria, Johnsson, Adam, Kling, Heather M., Powell, Ashley A., Untch, Sarah, Aquilanti, Elisa , Blondin, Nicholas, Boulmay, Brian C., Fuente, Macarena de la, Lobbous, Mina , Mikkelsen, Tom , Newton, Herbert B. , Schiff, David , Sherman, Wendy, Weathers, Shiao-Pei, Friend, John, Lee, E., Mellinghoff, Ingo K , Cloughesy, Timothy F. , Alexander, Brian M. , Cavenee, Webster K. , Colman, Howard , Groot, John de , Ellingson, Benjamin M. , Khasraw, Mustafa , Sulman, Erik P. , Weller, Michael , Wen, Patrick Yung , Johnsson, Adam, McGlothlin, Anna , Powell, Ashley, Drappatz, Jan , Jordan, Justin T. , Kaley, Thomas , Owen, Scott , Peters, Katherine B. , Schiff, David, Weathers, Shiao‐Pei , Youssef, Michael , Friend, John

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1302 Get It

Abstract GBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. Paxalisib, a PI3K/mTOR inhibitor, is the 3rd arm in the trial to conclude evaluation. METHODS Paxalisib was open to patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma, with three possible signatures: NDU, RD, and All(NDU+RD). Arm enrollment occurred Dec2020 through May2022. Control patients were enrolled from study initiation (July2019) and were treated with temozolomide(NDU) or lomustine(RD). GBM AGILE investigational arms have 1 or 2 stages, with adaptive randomization in stage 1 and fixed randomization if arms continue to stage 2. Efficacy is based on OS hazard ratio(HR) of Arm/Control. Efficacy goal is final Bayesian probability ≥ 98% for HR<1.00 in combined Stages. An Arm continues to Stage 2 if Bayesian predictive power (PP) ≥ 0.8. An Arm stops accruing in Stage 1 if it reaches maximal sample size(N) or does not meet a minimum efficacy threshold (PP<0.25 for all signatures when N>50). Clinical cut-off is 12 months after accrual stops. The maximum N for paxalisib was approximately 150(Stage 1) and 50(Stage 2). RESULTS After paxalisib reached >150 patients in Stage 1, accrual stopped [Paxalisib/control N 54/75(NDU), 100/188(RD)]. Neither PP thresholds for moving to Stage 2 nor stopping for minimum efficacy were met. Following an unplanned public disclosure that the arm did not continue to stage 2, clinical cut-off for final analysis (planned May2023) was updated to public disclosure date (August2022). At final analysis mean HRs were 0.89(NDU), 1.25(RD), 1.05(All), probabilities of HR<1.00 of 0.72(NDU), 0.076(RD), 0.398(All). Model estimated median OS paxalisib/control (months) were 14.77/13.84(NDU) and 8.58/10.06(RD). CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Zile, Michael R. , Borlaug, Barry A. , Kramer, Christopher M. , Baum, Seth J. , Litwin, Sheldon E. , Menon, Venu , Ou, Yang , Weerakkody, Govinda J. , Hurt, Karla, Murakami, Masahiro, Group, for the SUMMIT Trial Study, Murakami, Masahiro , Packer, Milton , Borlaug, Barry A , Zile, Michael R , Kanu, Chisom , Packer, Milton , Group, for the SUMMIT Trial Study

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 10 | Pages: 656-668

10.1161/circulationaha.124.072679 | PMID 39556714 Get It

BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m 2 to tirzepatide (titrated up to 15 mg SC weekly; n=364) or placebo (n=367) added to background therapy for a median of 104 weeks (quartile 1, 66; quartile 3, 126 weeks). The primary end points were whether tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The current expanded analysis included sensitivity analyses of the primary end points, 6-minute walk distance, EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health score, New York Heart Association class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and 6-minute walk distance. RESULTS: Patients were 65.2±10.7 years of age; 53.8% (n=393) were female; body mass index was 38.2±6.7 kg/m 2 ; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 53.5±18.5; 6-minute walk distance was 302.8±81.7 m; and 53% (n=388) had a worsening heart failure event in the previous 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time to first event (hazard ratios, 0.41–0.67). At 52 weeks, tirzepatide increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points (95% CI, 3.3–10.6; P <0.001), 6-minute walk distance 18.3 meters (95% CI, 9.9–26.7; P <0.001), and EQ-5D-5L 0.06 (95% CI, 0.03–0.09; P <0.001). The tirzepatide group shifted to a more favorable Patient Global Impression of Severity Overall Health score (proportional odds ratio, 1.99 [95% CI, 1.44–2.76]) and New York Heart Association class (proportional odds ratio, 2.26 [95% CI, 1.54–3.31]; both P <0.001) and required fewer heart failure medications ( P =0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.17–2.28]; P =0.004). CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04847557.
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Judge, Daniel P. , Gillmore, Julian D. , Ambardekar, Amrut V. , Cappelli, Francesco , Fontana, Marianna , Grodin, Justin L. , Grogan, Martha , Hanna, Mazen, Masri, Ahmad , Nativi-Nicolau, José , Sarswat, Nitasha , Shah, Keyur, Cao, Xiaofan, Wang, Kevin , Tamby, Jean‐François, Katz, Leonid , Sinha, Uma, Fox, Jonathan C. , Maurer, Mathew S. , Alexander, Kevin M , Ambardekar, Amrut V , Cappelli, Francesco , Fontana, Marianna , Garcia-Pavia, Pablo , Grodin, Justin L , Grogan, Martha , Masri, Ahmad , Nativi-Nicolau, Jose , Obici, Laura , Sarswat, Nitasha , Soman, Prem , Lystig, Ted , Fox, Jonathan C , Maurer, Mathew S , Gillmore, Julian D , Judge, Daniel P , Hanna, Mazen, Obici, Laura , Poulsen, Steen Hvitfeldt , Pecoraro, Maria Lucia

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 9 | Pages: 601-611

10.1161/circulationaha.124.072771 | PMID 39556242 Get It

BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46–0.72) at month 42 based on a stratified Cox proportional hazards model ( P <0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47–0.88) and 0.53 (95% CI, 0.41–0.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation. CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04988386.
Challenges and outcomes of airway surgery in a post‐war low‐resource setting: A case series from Mekelle, Ethiopia
Eyassu, Daniel G. , Candelo, Estephanía , Asgedom, Brhanu H. , Wallerius, Katherine P. , Twardus, Shaina W., Niermeyer, Weston L. , Green, Katerina J. , Athni, Tejas S. , Wiedermann, Joshua P. , Gomez, Estephania Candelo , Green, Katerina

Mayo Clinic

Laryngoscope Investigative Otolaryngology | November 18, 2024 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/lio2.70034 | PMID 39559464 Get It

AbstractObjectiveThis study aims to document and analyze the challenges and outcomes of performing complex airway surgery in a low‐resource, post‐war setting in Mekelle, Ethiopia.MethodsThis prospective case series examines clinical data from five patients who underwent airway reconstruction surgeries and one patient who underwent total laryngectomy at Ayder Comprehensive Specialized Hospital in Mekelle. Data included patient demographics, airway stenosis etiology and severity, operative details, postoperative outcomes, complications, and hospital length of stay. Ethical approval was obtained from institutional review boards at Mayo Clinic and Mekelle University.ResultsThe study included six patients aged 9–62 years, with surgeries comprising three cricotracheal resections, two tracheal resections, and one laryngectomy. Three reconstructions were for war‐related injuries. Challenges included power outages during surgeries, limitations in medical supplies and equipment, and inadequate perioperative care. Despite these, three patients requiring tracheostomies were successfully decannulated within a year. However, complications such as restenosis, infections, and the need for reintubation were common.ConclusionAirway surgeries in a low‐resource, post‐war setting face significant hurdles, including perioperative care quality, resource limitations, and infrastructure issues. Successful outcomes require multidisciplinary training tailored to local contexts, investments in hospital infrastructure and reliable electricity, and proper perioperative nutrition. This study highlights the need for comprehensive interventions to improve surgical care in such settings.Level of evidence: IV.
AAPM task group report 314: Fault recovery in external beam radiation therapy
Sutlief, Steven , Buckey, C, Hadley, Scott, Curran, Bruce, Siochi, R , Tripathi, Sugata , Perrin, D, Young, Cheryl, Negrut, Cristina, Koehl, Susan, Shi, Jie, Ibbott, Geoffrey S. , Young, Cheryl, Robertson, Ian

Mayo Clinic

Medical Physics | November 15, 2024 | Volume: 52 | Issue: 1 | Pages: 21-44

10.1002/mp.17502 | PMID 39545768 Get It

Abstract Task Group (TG) 314 of the American Association of Physicists in Medicine (AAPM) was charged to develop guidance for recovering from fault states in radiation therapy, specifically regarding the delivery of photon or electron beams using a linear accelerator (linac) including ancillary systems. The fault conditions addressed may involve software, hardware, or a combination of causes. The report provides detailed recommendations for the proactive steps to be taken before a fault, the actions to be taken at the time of a fault, and the safety steps before returning a linac to clinical service, as well as the activities that device manufacturers and standard organizations can do to prevent and resolve the faults. A user‐maintained log of prior faults; establishment of remote access by the vendor; and user training in emergency gantry, couch, and door motions are all useful proactive steps. At the moment of downtime and after ensuring the safety of the patient, the report stresses the importance of capturing fault information, prompt contact with the service engineer after the initial assessment, and considerations for communicating the estimated duration before the linac is returned to service. The medical physicist has a critical responsibility to assess the impact of the fault on patient care. Before resuming clinical use, the medical physicist must both determine the level of testing required to ensure safe operation of the linac and ensure any partially or totally delivered treatments have been correctly saved for accurate completion of the treatment fraction. The report stresses the roles of the radiation therapist, medical physicist, and service engineer to efficiently and safely address linac downtime. The appendices contain a description of the efforts of several organizations regarding linac safety: Integrating the Healthcare Enterprise—Radiation Oncology, International Standards Organization/International Electrotechnical Commission, Radiation Oncology Safety Stakeholder Initiative, and the AAPM Vendor Relations and Product Usability Subcommittee. Disclaimer: The recommendations of this TG should not be used to establish regulations. These recommendations are guidelines for Qualified Medical Physicists and others to use and appropriately interpret for their institution and clinical setting. Each institution may have site‐specific or state‐mandated needs and requirements which may modify their usage of these recommendations.
Abstract 4147141: Relationship Between CVH and Survival in the Acoramidis Treated Participants Within ATTRibute-CM
Davis, Margot K. , Ambardekar, Amrut, Nativi-Nicolau, José , Shah, Keyur B. , Hanna, Mazen, Gibbs, Simon, Tamby, Jean‐François, Siddhanti, Suresh , Whang, John , Fox, Jonathan C. , Du, Jing, Cheng, Richard K. , Cheng, Richard , Alexander, Kevin M , Ambardekar, Amrut V. , Hanna, Mazen

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147141 Get It

Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in near-complete (≥90%) TTR stabilization. In a phase 3 study, ATTRibute-CM, acoramidis demonstrated improved clinical outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM), including a 50% reduction in the risk of CVH compared to placebo over 30 months. The study also demonstrated that cardiovascular hospitalization (CVH) during the study predicted a higher subsequent mortality in participants with ATTR-CM. Hypothesis: CVH portends a higher risk of mortality in participants with ATTR-CM. Since acoramidis reduces CVH, it can improve the prognosis of participants with ATTR-CM. Aim: To evaluate the relationship between CVH and survival in the acoramidis group within ATTRibute-CM. Methods: In this post-hoc analysis, the relationship between those with or without CVH and survival was analyzed within the acoramidis treatment group using the Kaplan-Meier (KM) estimator method. Results: Demographics and baseline disease characteristics were mostly comparable between acoramidis-treated participants with and without CVH, although participants with CVH had a higher baseline NT-proBNP and lower eGFR. At Month 30, in acoramidis-treated participants, those without any CVH (n=300) had a higher survival [86.8% (95% CI = 82.2, 90.3)] versus 62.4% (95% CI = 52.6, 70.7) in those who had any CVH (n=109); p<0.0001 from log-rank test (Figure). Conclusion: In the ATTRibute-CM study, pts without any CVH receiving acoramidis have a higher survival rate. CVHs remain a powerful predictor of mortality. This reinforces the importance of an effective therapy that reduces CVH and in turn may improve survival in patients with ATTR-CM.
Abstract 4145990: Time Trend Analysis of Clinical Outcomes for Drug-Coated Balloon versus Drug-Eluting Stent among Patients with Coronary In-Stent Restenosis: A Meta-Analysis of Randomized Controlled Trials
Shojaei, Shayan , Moghadam, Saman Soltani, Ebrahimi, Rasoul, Shirmard, Fatemeh Ojaghi , Pourfaraji, Seyed Morteza , Hobaby, Sara , Soleimani, Hamidreza , Tehrani, Behnam , Elgendy, Islam Y. , Basavarajaiah, Sandeep , Elgendy, Islam Y , Moghadam, Arman Soltani , Kazemian, Sina , Dolama, Reza Hosseini , Ebrahimi, Rasoul , Najafi, Mohammad Sadeq , Allana, Salman , Raphael, Claire E. , Hosseini, Kaveh

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4145990 Get It

Background: Coronary in-stent restenosis (ISR) secondary to neointimal hyperplasia or neoatherosclerosis remains a significant challenge following percutaneous coronary interventions (PCI), with no consensus on the optimal revascularization strategy. We compared the outcome of PCI for ISR using drug-coated balloons (DCB) and drug-eluting stents (DES) and investigated the time trends in their clinical outcomes. Methods: PubMed, Embase, Scopus, and the Cochrane Library databases were searched through May 2024. We included randomized controlled trials (RCTs) comparing DCB versus DES among patients with coronary ISR. The primary outcome was target lesion revascularization (TLR). Secondary outcomes included all-cause mortality, myocardial infarction (MI), stent thrombosis, and late lumen loss (LLL). Random-effects models were employed to analyze outcomes within 1-year and beyond 1-year intervals. Meta-regression analysis was used to investigate the effect of age, sex, history of diabetes, hypertension, dyslipidemia, smoking, and ejection fraction on all outcomes by applying mixed-effect models. Results: We included 10 RCTs (1034 patients in the DCB group and 943 patients in the DES group). We found similar incidence of 1-year TLR (odds ratio [OR] 1.36; 95% confidence interval [CI] 0.86, 2.14; P 0.194; I 2 43.3%) and >1-year TLR (OR 0.94; 95% CI 0.57, 1.56; P 0.817; I 2 0%) with the use of DCB versus DES. The risks of all-cause mortality, MI, and stent thrombosis were comparable between DCB and DES in 1-year and beyond 1-year follow-ups. At 6-9 months angiographic follow-up, DCB was associated with non-significantly lower LLL compared to DES (standardized mean difference [SMD] -0.12 millimeters; 95% CI -0.29, 0.05; P 0.170; I 2 71.7%). Meta-regression indicated that higher prevalence of diabetes was associated with an increased risk of 1-year revascularization after DCB compared to DES (Estimate 0.07; P 0.003; I 2 0%). Additionally, male sex was associated with an increased LLL in DCB versus DES (Estimate 0.034; P 0.001; I 2 41.8%). No association was found between other baseline characteristics and measured clinical outcomes. Conclusion: DCB demonstrated comparable PCI outcomes compared to DES in patients with coronary ISR.